↓ Skip to main content

Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain

Overview of attention for article published in BMC Infectious Diseases, October 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (82nd percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

policy
2 policy sources
twitter
7 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
65 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
Published in
BMC Infectious Diseases, October 2017
DOI 10.1186/s12879-017-2803-0
Pubmed ID
Authors

M. Sanchez-Luna, R. Burgos-Pol, I. Oyagüez, J. Figueras-Aloy, M. Sánchez-Solís, F. Martinón-Torres, X. Carbonell-Estrany

Abstract

This study aimed at estimating the efficiency of palivizumab in the prevention of Respiratory Syncytial Virus (RSV) infection and its sequelae in preterm infants (32(day 1)-35(day 0)weeks of gestational age -wGA-) in Spain. A decision-tree model was developed to compare health benefits (Quality Adjusted Life Years-QALYs) and costs of palivizumab versus a non-prophylaxis strategy over 6 years. A hypothetical cohort of 1,000 preterm infants, 32(day 1)-35(day 0) wGA (4.356 kg average weight) at the beginning of the prophylaxis (15 mg/kg of palivizumab; 3.88 average number of injections per RSV season) was analysed. The model considered the most recent evidence from Spanish observational and epidemiological studies on RSV infection: the FLIP II study provided hospital admission and Intensive Care Unit (ICU) admission rates; in-hospital mortality rate was drawn from an epidemiological study from 2004 to 2012; recurrent wheezing rates associated to RSV infection from SPRING study were adjusted by the evidence on the palivizumab effect from clinical trials. Quality of life baseline value, number of hospitalized infants and the presence of recurrent wheezing over time were granted to estimate QALYs. National Health Service and societal perspective (included also recurrent wheezing indirect cost) were analysed. Total costs (€, 2016) included pharmaceutical and administration costs, hospitalization costs and recurrent wheezing management annual costs. A discount rate of 3.0% was applied annually for both costs and health outcomes. Over 6 years, the base case analysis showed that palivizumab was associated to an increase of 0.0731 QALYs compared to non-prophylaxis. Total costs were estimated in €2,110.71 (palivizumab) and €671.68 (non-prophylaxis) from the National Health System (NHS) perspective, resulting in an incremental cost utility ratio (ICUR) of €19,697.69/QALYs gained (prophylaxis vs non-prophylaxis). Results derived from the risk-factors population subgroups analysed were in line with the total population results. From the societal perspective, the incremental cost associated to palivizumab decreased to an €1,253.14 (ICUR = €17,153.16€/QALYs gained for palivizumab vs non-prophylaxis). One-way and probabilistic sensitivity analyses confirmed the robustness of the model. The prophylaxis with palivizumab is efficient for preventing from RSV infections in preterm infants 32(day 1)-35(day 0) wGA in Spain.

Twitter Demographics

The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 65 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 10 15%
Student > Master 8 12%
Other 6 9%
Student > Bachelor 5 8%
Student > Ph. D. Student 5 8%
Other 7 11%
Unknown 24 37%
Readers by discipline Count As %
Medicine and Dentistry 19 29%
Pharmacology, Toxicology and Pharmaceutical Science 4 6%
Nursing and Health Professions 4 6%
Agricultural and Biological Sciences 3 5%
Economics, Econometrics and Finance 3 5%
Other 7 11%
Unknown 25 38%

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 January 2020.
All research outputs
#2,147,320
of 17,366,233 outputs
Outputs from BMC Infectious Diseases
#651
of 6,154 outputs
Outputs of similar age
#58,851
of 330,429 outputs
Outputs of similar age from BMC Infectious Diseases
#95
of 670 outputs
Altmetric has tracked 17,366,233 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,154 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.5. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,429 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 670 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.